Immunomodulatory properties of cefaclor: In vivo effect on cytokine release and lymphoproliferative response in rats

Journal of Chemotherapy

Volumn 18, Issue 6, 2006, Pages 641-647

  Mangano, Katia ^a,b   Quattrocchi, C ^a   Aiello, C ^a   Scalia, G ^a   Speciale, A ^a   Nicoletti, G ^a   Di Marco, R ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

Author keywords

Antibiotics; Cefaclor; Cytokines; Immunity; Lymphocyte

Indexed keywords

CEFACLOR; CEPHALOSPORIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PHYTOHEMAGGLUTININ;

ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; EX VIVO STUDY; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; RAT; SPLEEN CELL;

EID: 33845979103     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2006.18.6.641     Document Type: Article

References (15)

1. Hamilton-Miller JM. Immunopharmacology of antibiotics: direct and indirect immunomodulation of defence mechanisms. J Chemother 2001;13(2):107-11.
2. Parnham MJ Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections Curr Opin Infect Dis 2005;18(2):125-31.
3. Takahashi HK, Iwagaki H, Xue D, et al. Effect of ciprofloxacin-induced prostaglandin E2 on interleukin-18-treated monocytes. Antimicrob Agents Chemother 2005;49(8):3228-33.
4. Katsuno G, Takahashi HK, Iwagaki H, et al. The immunosuppressive effects of ciprofloxacin during human mixed lymphocyte reaction. Clin Immunol 2006;119(1):110-9. Epub 2006 Feb 2.
5. Nicoletti F, Meroni PL, Bendtzen K. Fusidic acid and insulin-dependent diabetes mellitus. Autoimmunity 1996;24(3):187-97.
6. Dabrowski MP, Stankiewicz W. Desirable and undesirable immunotropic effects of antibiotics: immunomodulating properties of cefaclor. J Chemother 2001;13(6):615-20.
7. Periti P. Immunopharmacology of oral betalactams. J Chemother 1998;10(2):91-6.
8. Scheffer J, Konig W. Cephalosporins and inflammatory host reactions. Respiration 1993;60 Suppl 1:25-31.
9. Scheffer J, Knoller J, Cullmann W, Konig W. Effects of cefaclor, cefetamet and Ro 40-6890 on inflammatory responses of human granulocytes. J Antimicrob Chemother 1992;30(1):57-66.
10. Stubner G. The effect of sub-inhibitory concentrations of cefaclor, erythromycin and doxycycline on phagocytosis and intracellular killing of E. coli by human neutrophil granulocytes. Arzneimittelforschung 1986;36(11):1702-4.
11. McGuirk P, Mills KH. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002;23(9):450-5.
12. Aoki N, Xing Z. Use of cytokines in infection. Expert Opin Emerg Drugs 2004;9(2):223-36.
13. Kaufmann SH, Schaible UE. Antigen presentation and recognition in bacterial infections. Curr Opin Immunol 2005;17(1):79-87.
14. Nicoletti F, Mancuso G, Cusumano V, Di Marco R, Zaccone P, Bendtzen K, Teti G. Prevention of endotoxin-induced lethality in neonatal mice by interleukin-13. Eur J Immunol 1997;27(6):1580-3.
15. Ferrante A. Activation of neutrophils by interleukins-1 and -2 and tumor necrosis factors. Immunol Ser 1992;57:417-36.